



## Curriculum Vitae

Personal information **Jens Reinhardt**

### Work experience

---

1. Employer: Paul\_Ehrlich\_Institut
  - Start date: 072019
  - End date:
  - Position: Deputy Head Department coagulation products II; now "assessment Quality Coagulation Products and Gene Therapy"
  - Activities: Evaluation of clinical trial applications and marketing authorisations for blood products, ATMP and influenza vaccines, scientific advice both on national and European level
  - Country: Germany
2. Employer: Paul\_Ehrlich\_Institut
  - Start date: 022008
  - End date: 062019
  - Position: scientific assessor/regulatory scientist
  - Activities: Evaluation of clinical trial applications and marketing authorisations for blood products, ATMP and influenza vaccines, scientific advice both on national and European level
  - Country: Germany
3. Employer: GPC Biotech AG
  - Start date: 042007
  - End date: 122007
  - Position: Scientist II
  - Activities: Basic research on cellular interaction partners of kinase inhibitors
  - Country: Germany
4. Employer: Station biologique Roscoff, CNRS
  - Start date: 112003
  - End date: 032007
  - Position: Scientist
  - Activities: Basic research on Kinase inhibitors
  - Country: France
5. Employer: Stanford University
  - Start date: 042002
  - End date: 102003
  - Position: Postdoctoral Scientist
  - Activities: Research on Cytomegalovirus
  - Country: United States

### Education and training

---

1. Subject: University of Giessen, Marburg and RKI, Berlin
  - Start date: 011997
  - End date: 102001
  - Qualification: Ph.D student
  - Organisation:
  - Country: Germany

### Additional information

---

#### Publications

36) Jens Reinhardt, Chancelar Kafere, Albert Maqolo, Goran Abdurrahman, Emmanuel Willie, Aggrey Phiri, Kapunda Masuwa, Frank Laban, Abhimanyu Shivhare, Ivan Emil Mwikarago, Khanyisile Nkuku, Erick Kitangala, Hafiza Moges, Edina Zebedayo, Joseph Donkor Issachar, Linda Nhukarume, Arinzechukwu Ikemefuna, Saren Shifotoka, Lilian Mutesi: *The current state of IVD evaluation in sub-Saharan African countries – insights from the advanced workshop (submitted)*

35) Washington T. Samukange, Verena Kluempers, Chancelar Kafere, Kristina Heinrich, Joanna Atemnkeng, Alireza Khadem Broojerdi, Florence Tirane, Edwin Nkansah, Shani Maboko, Linda Nhukarume, Khamusi Mutoti, Noel Aineplan, Helga Gardasdottir, Aukje K. Mantel-Teeuwisse & **Jens Reinhardt**: Bridging the Gap: Enhancing Blood Regulatory Functions in African contexts through Comparative

34) Goran Abdurrahman, Washington Samukange, Nyambe Lyoko, Negus Onai Shonhiwa, Chancelar Kafere, C. Micha Nübling, Rosanna W Peeling, **Jens Reinhardt**: Regulation of blood-screening in vitro diagnostics in sub-Saharan African countries remains a challenge, (Front Med (Lausanne). 2023 Oct 3;10:1252721. doi: 10.3389/fmed.2023.1252721)

33) Washington T. Samukange, Chancelar Kafere, Kristina Heinrich, George T. Sabblah, Mwewa M. Siame, Libert Chirinda, **Jens Reinhardt**, Anneliese Hilger: Strengthening Blood Regulatory Systems can tackle Africa's unmet needs for blood and blood products. **Transfus Med Hemother.** 2022 Dec 22; 50(2): 123-128

32) Herbert A. Mbunkah, Chancelar Kafere, Washington Samukange, Micha Nübling, **Jens Reinhardt**: Congress Report: Online workshop on Assessment of Technical Files for Blood Screening In Vitro Diagnostics for sub-Sahara African countries. **Transfus Med.** 2022 Dec; 32(6):467-474

31) Joanna Atemnkeng, Kristina Heinrich, Washington T. Samukange, Chancelar Kafere, Herbert A. Mbunkah, Christine Schoner, **Jens Reinhardt**: Report from the GHPP-BloodTrain Online Workshop on "Authorisation and Licensing of Blood Establishments - Review of Quality Documentation of Blood and Blood Components", 5th-8th of July 2021. **Biologicals.** 2022 Oct;80:c1-5.

30) Washington T. Samukange, Verena Klümpers, Chancelar Kafere, Frank Schuler, Florence Jonazi Tirane, Beatrice Kabaso, David Chama, Edwin Ajiga Ejeh, and **Jens Reinhardt**: "Report from the GHPP-BloodTrain Inspection Workshop in Harare the 20th to the 24th of May 2019", **Biologicals**, 2020 Nov;68:125-128. doi: 10.1016/j.biologicals.2020.08.012

29) Mbunkah, Herbert; **Reinhardt, Jens**; Kafere, Chancelar; Scheiblaue, Heinrich; Prat, Irena; Nübling, Claudius: „In vitro diagnostics for screening the blood supply: The new European regulation for IVD and the WHO IVD prequalification program"; **Vox Sanguinis**, DOI:10.1111/vox.12996

28) Kafere C, Tayou Tagny C, Tapko JB, Mbunkah HA, Samukange WT, Mutoti K, Mudyinyama L, Sumaila A, **Reinhardt J**: "Congress Report: Implementation of Blood and Blood Product Regulation Training Workshop, South Africa "; **Africa Sanguine** 2020, Volume 22, Number 1

27) Müller MM, Schmidt M, **Reinhardt J**: Bericht vom internationalen Expertentreffen der Weltgesundheitsorganisation zu „emerging infections“ und Blutsicherheit, **hämotherapie** 2017, 29, p21-228

26) Lauren Scarfe, Nathalie Brillant, J. Dinesh Kumar, Noura Ali, Ahmed

Alrumayh, Mohammed Amali, Stephane Barbellion, Vendula Jones, Marije Niemeijer, Sophie Potdevin, Gautier Roussignol, Anatoly Vaganov, Ivana Barbaric, Michael Barrow, John Connell, Francesco Dazzi, Josefina Edsbagge, Neil S. French, Julie Holder, Claire Hutchinson, David R. Jones, Tammy Kalber, Cerys Lovatt, Mark F. Lythgoe, Sara Patel, P. Stephen Patrick, Jacqueline Piner, **Jens Reinhardt**, Emanuelle Ricci, James Sidaway, Glyn Stacey, Philip Starkey-Lewis, Gareth Sullivan, Arthur Taylor, Bettina Wilm, Harish Poptani, Patricia Murray, Chris E. P. Goldring, B. Kevin Park (2017): Preclinical imaging methods for assessing the safety and efficacy of regenerative medicine therapies. **Nature Regenerative Medicine** npj Regenerative Medicine 2, Article number: 28 (2017), doi:10.1038/s41536-017-0029-9

25) Nils Jost, Martina Schüssler-Lenz, Bettina Ziegele, Jens Reinhardt (2015). Nationale und EMA wissenschaftliche Beratung von Arzneimitteln für neuartige Therapien. **Bundesgesundheitsblatt – Gesundheitsforschung – Gesundheitsschutz**, 2015 Nov; 58 (11-12):1207-14.

24) James A. Heslop, Thomas G. Hammond, Ilaria Santeramo, Agnès Tort Piella, Isabelle Hopp, Jing Zhou, Roua Baty, Enrique I. Graziano, Proto Marco Bernabe, Alexis Caron, David A. Shaw, Ian Bunn, Patrik Sköld, Peter W. Andrews, Melissa A. Baxter, David Hay, Junnat Hamdam, Swaminathan Sethu, Michaela E. Sharpe, Sara Patel, David R. Jones, **Jens Reinhardt**, Erik H.J Danen, Uri Ben-David, Glyn Stacey, Petter Björquist, Cliff Rowe, Giovanni Pellegrini, Daniel J. Antoine, Michael J. Cross, Patricia Murray, Dominic Williams, Neil R. Kitteringham, Chris E.P. Goldring and B. Kevin Park (2015): Concise Review: Workshop Review: Understanding and Assessing the Risks of Stem Cell-Based Therapies. [Stem Cells Transl Med.](#) 2015 Apr;4(4):389-400

23) Egbert Flory, **Jens Reinhardt** (2013) European Regulatory Tools for Advanced Therapy Medicinal Products. **Transfusion Medicine and Haemotherapy**, 2013; 40:409 - 412

22) **Jens Reinhardt**, Egbert Flory, Isabel Christine Büttel, Christa Schröder, Stefan Fricke, Vladan Vucinic, Michael Cross, and Dietger Niederwieser (2013) MSCs: Clinical Applications and European Regulatory Aspects (Book Chapter); in P. Hematti, A. Keating (Eds.), Mesenchymal Stromal Cells: Biology and Clinical Applications, Stem Cell Biology and Regenerative Medicine, DOI 10.1007/978-1-4614-5711-4\_18, Springer Science + Business Media, New York 2013

21) Klug B, Celis P, Carr M, **Reinhardt J.** (2012): Regulatory structures for gene therapy medicinal products in the European Union. **Methods Enzymol.** 2012;507:337-54.

20) Bettina Klug, **Jens Reinhardt**, and James Robertson (2012): Current Status of Regulations for DNA Vaccines (Book Chapter); in J. Thalhamer et al. (eds.), Gene Vaccines, Springer-Verlag / Wien, 2012, p

19) Hamdorf, M., Berger, A., Schüle, S., **Reinhardt, J.**, and Flory, E. (2011) PKC $\delta$ -induced PU.1 phosphorylation promotes hematopoietic stem cell differentiation to dendritic cells. **Stem Cells** 29: 297–306. doi: 10.1002/stem.564

18) **Jens Reinhardt**, Johannes Bluemel, Albert Stuehler (2011) Safety of bovine sera at production of mesenchymal stem cells at therapeutic use. **Human Gene Therapy** – Letter to the editor (2011, Jun; 22 (6):775)

17) Goldring C, Andrews P, Ben-David U, Benvenisty N, Davies A, Eakins R, French N, Hanley N, Kelly L, Kitteringham NR, Kurth J, Ladenheim D, Laverty H, McBlane J, Narayanan R, Park BK, Patel S, **Reinhardt J**, Rossi A-M, Sharpe M, Duffy P. (2011) Assessing the Safety of Stem Cell Therapeutics. **Cell Stem Cell**, 2011 Jun 3; 8 (6):618-28.

16) **Jens Reinhardt**, Christa Schröder, Karl Feiden (2010) Regenerative Medizin: Gewebegesetz und Neuartige Therapien zur Regeneration. **Deutsche Apotheker-Zeitung** (2010, Nr. 45, S. 57-61)

15) Philip Kasten, Peter Bernstein, Achim Biewener, Martin Bornhäuser, Georg N. Duda, Christoph Gaissmaier, Ulrich Nöth, Barbara Pfüller, **Jens Reinhardt**, Hans Zwipp, Klaus-Peter Günther (2010); Perspektiven klinischer mesenchymaler Stammzelltherapie bei muskuloskeletalen Erkrankungen in Deutschland- Eine Standortbestimmung; **Zeitschrift für Orthopädie und Unfallchirurgie** (2010 Jan 28, Epub ahead of print)

14) Salmikangas, Paula, Flory, Egbert, **Reinhardt, Jens**, Hinz, Thomas and Maciulaitis, Romaldas (2009), Regulatory requirements for clinical trials and marketing authorisation application for cell-based medicinal products, **Bundesgesundheitsblatt - Gesundheitsforschung – Gesundheitsschutz** in press; published online 27. November 2009, DOI 10.1007/s00103-009-0991-5

13) Bettina Klug, **Jens Reinhardt**, Christa Schröder (2009); Regelungen zur Überwachung von Wirksamkeit und Sicherheit nach der Zulassung, Risikomanagement und Rückverfolgbarkeit von Arzneimitteln für Neuartige Therapien, **Bundesgesundheitsblatt - Gesundheitsforschung – Gesundheitsschutz** in press; published online: 2. Dezember 2009, DOI 10.1007/s00103-009-0992-4

12) Bettina Klug, **Jens Reinhardt**, Matthias Renner, Hartmut Krafft, Klaus Cichutek (2009), Anforderungen an die klinische Prüfung von Arzneimitteln für neuartige Therapien, **onkopipeline** 2009; 2 (Nr.3); 86-91

11) **Jens Reinhardt**, Evelyne Kretzschmar, Klaus Cichutek (2009), Paul-Ehrlich-Institut: A Federal Research and Regulatory Institute with international competence for vaccines and biomedicines, **Hessen**

10) **Reinhardt, J.**, Ferandin, Y., Meijer, L (2007), Purification of CK1 by affinity chromatography. **Protein Expression & Purification** 54 (1), 1 July 2007: 101-109

9) Iurisci, I., Filipski, E., **Reinhardt, J.**, Bach, S., Gianella-Borradori, A. , Iacobelli, S., Meijer, L. and Lévi, F. (2006), Improved tumor control and cell cycle inhibition through circadian clock induction. **Cancer Research** 66 (22): 10720-10728.

8) Holtzendorff, J., **Reinhardt, J.**, Viollier, P.H. (2006), Cell cycle control by oscillating regulatory proteins in *Caulobacter crescentus*, **BioEssays**, 28, 355-361

7) Bach, S., Knockaert, M., **Reinhardt, J.**, Lozach, O., Schmitt, S., Baratte, B., Koken, M., Coburn, S. P., Tang, L., Jiang, T., Liang, D. C., Galons, H., Dierick, J. F., Pinna, L. A., Meggio, F., Totzke, F., Schachtele, C., Lerman, A. S., Carnero, A., Wan, Y., Gray, N., Meijer, L. (2005). Roscovitine targets, protein kinases and pyridoxal kinase. **J Biol Chem** 280, 31208-31219.

6) Tang, L., Li, M. H., Cao, P., Wang, F., Chang, W. R., Bach, S., **Reinhardt, J.**, Ferandin, Y., Galons, H., Wan, Y., *et al.* (2005). Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives. **J Biol Chem** 280, 31220-31229.

5) **Reinhardt, J.**, Smith, G.B., Himmelheber, C.T., Azizkhan-Clifford, J., and Mocarski, E.S. (2005) The Carboxyl-terminal Region of Human Cytomegalovirus IE1491aa Contains an Acidic Domain that Plays a Regulatory Role and a Chromatin-tethering Domain that is Dispensable during Viral Replication. **J Virol** 2005 January, Vol. 79, No 1; pp 225 – 233

4) Ludwig, S., Wolff, T., Ehrhardt, C., Wurzer, W.J., **Reinhardt, J.**, Planz, O. and Pleschka, S. (2004) MEK-Inhibition impairs Influenza B Virus Propagation without Emergence of Resistant Variants. **FEBS Letters**, Vol 561, Iss 1-3;37 - 43

3) **Reinhardt, J.**, Wolff, T (2000) The influenza A virus M1 protein interacts with the cellular receptor of activated C kinase (RACK) 1 and can be phosphorylated by protein kinase C. *Vet Microbiol.* 2000 May 22;74(1-2): 87 – 100

2) Wolff, T., Pflieger, R., Wehner, T., **Reinhardt, J.**, Richt, J.A. (2000) A short leucine-rich sequence in the Borna disease virus p10 protein mediates association with the viral phospho- and nucleoproteins. **J Gen Virol.** 2000 Apr; 81 Pt 4: 939-47.

1) **Reinhardt, J.** & Wolff, T. (2002) [Interaction of influenza virus with the host cell: A fatal connection] (german), *Bundesgesundheitsblatt* -

[Projects](#)

[Memberships](#)

[Other Relevant Information](#)